Objective: To determine an effective, evidence-based, postoperative surveillance strategy for the detection and treatment of recurrent breast cancer. Tests are recommended only if they have an impact on the outcomes specified by American Society of Clinical Oncology (ASCO) for clinical practice guidelines. Potential Intervention: All tests described in the literature for postoperative monitoring were considered, In addition, the data were critically evaluated to determine the optimal frequency of monitoring. Outcome: Outcomes of interest include overall and disease-free survival, quality of life, toxicity reduction, and secondarily cost-effectiveness. Evidence: A search wets performed to determine all relevant articles published over the past 20 years on the efficacy of surveillance testing for breast cancer recurrence. These publications comprised both retrospective and prospective studies. Values: Levers of evidence and guideline grades were rated by a standard process. More weight was given to studies that tested a hypothesis directly relating testing to one of the primary outcomes in a randomized design. Benefits, Harms, and Costs: The possible consequences of false-positive and -negative tests were considered in evaluating ct preference for one of two tests providing similar information. Cost alone was not a determining factor. Recommendations: The attached guidelines and text summarize the updated recommendations of the ASCO breast cancer expert panel, Data are sufficient to recommend monthly breast self-examination, annual mammography of the preserved and contralateral breast, and a careful history and physical examination every 3 to 6 months for 3 years, then every 6 to 12 months for 2 years, then annually. Data are not sufficient to recommend routine bone scans, chest radiographs, hematologic blood counts, tumor markers (carcinoembryonic antigen, cancer antigen [CA] 15-5, and CA 27.29), liver ultrasonograms, or computed tomography scans. Validation: The recommendations of the breast cancer expert panel were evaluated and supported by the ASCO Health Services Research Committee reviewers and the ASCO Board of Directors. Sponsor American Society of Clinical Oncology. (C) 1999 by American Society of Clinical Oncology.
